Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.
The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® ...
President Donald Trump announced major GLP-1 drug price cuts with Eli Lilly and Novo Nordisk, reducing costs for Ozempic and Wegovy.
This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...
Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...
Investing.com -- Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the ...
The US president’s sudden policy reversal on weight-loss drugs like Ozempic and Wegovy could reshape the global market, from ...
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
Daily Voice on MSN
Trump Slashes Prices For Ozempic, GLP1s
GLP-1s are about to get more affordable in the United States, thanks to a new deal announced Thursday, Nov. 6 by the Trump ...
The deal offers popular weight loss drugs to be sold for as low as $149 on President Donald Trump's direct-to-consumer ...
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy through TrumpRx for $350 and Eli Lilly and Company's Zepbound and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback